SynthesisJournal of neuro-oncology2026
Survival and hematologic toxicity after whole-brain radiotherapy, photon craniospinal irradiation, and proton craniospinal irradiation for solid-tumor leptomeningeal disease: a systematic review.
Synthesis in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeptomeningeal disease (LMD) from solid tumors carries poor prognosis and substantial neurologic morbidity. Radiotherapy is used for palliation and disease control, but outcomes across whole-brain radiotherapy (WBRT), photon craniospinal irradiation (CSI), and proton CSI remain incompletely defined.
methodsWe conducted a PRISMA-based systematic review of PubMed-indexed studies reporting radiotherapy outcomes for adult solid-tumor LMD. Studies were categorized as photon WBRT/non-CSI, photon CSI, or proton CSI. Primary outcomes were median overall survival (OS) and progression-free survival (PFS), including CNS-PFS or intracranial PFS when reported. Grade ≥ 3 hematologic and non-hematologic toxicities were extracted when available.
resultsThirty-two unique studies/reports were included: 21 photon WBRT/non-CSI, 6 photon CSI, and 6 proton CSI studies. The median of reported median OS values were 4.5 months for photon WBRT/non-CSI, 4.1 months for photon CSI, and 10.7 months for proton CSI. Median PFS was 3.9 months for photon WBRT/non-CSI and 4.6 months for proton CSI; no extractable median PFS was available for photon CSI. Among studies with extractable denominators, crude pooled grade ≥ 3 hematologic toxicity was 2.8% for photon WBRT/non-CSI, 80.0% for photon CSI, and 59.4% for proton CSI; however, toxicity reporting was limited and heterogeneous.
conclusionProton CSI cohorts had numerically longer reported survival, but cross-study comparisons are limited by heterogeneity, treatment-era and selection differences, and systemic therapy exposure. These findings do not establish superiority over photon CSI and warrant prospective comparative evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.